Many patients treated with oxaliplatin experience sensory deficits in the distal extremities. This impairment may persist for several months after treatment is discontinued, resulting in a negative impact on quality of life. Statins, which are used to treat dyslipidemia, have a pleiotropic action, such as anti-inflammatory effect. Here we show that statins can be a therapeutic agent for oxaliplatin-induced peripheral neuropathy via the regulation of glutathione S-transferase (GST). The mechanical hypersensitivity induced by oxaliplatin was ameliorated on day 7 in mice repeated orally administered statins and lasted for 21 days. Furthermore, mechanical hypersensitivity was suppressed even when statins were administered after day 7 of oxaliplatin exposure. On the other hand, statins were not effective against cold hyperalgesia. Uptake of oxaliplatin in the DRG was not inhibited by statins. Analysis of gene association databases revealed that the expression of GST family members is regulated by statins. Co-administration of the GST inhibitor, ethacrynic acid, reversed the statin-induced suppression of oxaliplatin-induced mechanical allodynia. Statins might be potential therapeutic agents for the treatment of anticancer drug-induced chronic peripheral neuropathy that do not suppress the effects of oxaliplatin.